SurVaxM
- Generic Name
- SurVaxM
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2416847-76-0
- Unique Ingredient Identifier
- HK7BJ56KSP
- Associated Conditions
- -
- Associated Therapies
- -
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 132
- Registration Number
- NCT06202066
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
SurVaxM Expanded Access Protocol
- Conditions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT04802447
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- David Peereboom
- Target Recruit Count
- 41
- Registration Number
- NCT04013672
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT03879694
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath